Synagis (Palivizumab) - Current Clinical Trials

Synagis Related Clinical Trials

Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA [Recruiting]

A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis) [Completed]

Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of MEDI-493, Synagis [Active, not recruiting]

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions [Recruiting]

Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 30-32 Weeks of Gestation [Not yet recruiting]

A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America [Recruiting]

Tetracaine Compared to Placebo for Reducing Pain With Palivizumab - A Pilot Study [Completed]

Study of Motavizumab (MEDI-524) and Palivizumab in the Same Respiratory Syncytial Virus (RSV) Season [Completed]

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MEDI-524 After Dosing for a Second Season in Children [Completed]

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation [Active, not recruiting]

Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy [Recruiting]

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease [Active, not recruiting]

Role of Human Milk Bank in the Protection of Severe Respiratory Disease in Very Low Birth Weight Premature Infants [Not yet recruiting]

Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants [Completed]